Picard Medical, Inc. Update: Fighting Back Against a Listing Warning

Picard Medical (PMI) makes the world's only FDA-approved temporary artificial heart. The company recently went public under the ticker PMI, and it is already tackling some balance sheet issues. While Picard's first-quarter results for 2026 show great business progress, management is also aggressively restructuring its finances to keep its stock exchange listing.

Here is what you need to know if you are thinking about investing.

1. What happened?

In May 2026, the NYSE American stock exchange sent Picard two warning notices. The exchange flagged Picard because its net worth fell below the required minimum.

Because Picard spent heavily on research to develop its complex artificial heart technology, its net worth fell to negative $1.4 million by March 31, 2026. In simple terms, the company owed more than it owned. To warn investors, the exchange added "BC" (Below Compliance) to the ticker, changing it to PMI.BC for the time being.

2. The Good News: Picard is Fighting Back

Picard's latest results and recent financial moves show a strong, active comeback plan:

• Sales are Surging: Sales jumped 85% compared to last year, reaching $1.2 million for the quarter. More U.S. hospitals are buying these artificial hearts, and Picard is earning steady rental income from its "Freedom Drivers" (the portable machines that power the hearts).
• Making Money on Products: For the first time, Picard made a profit on the physical products it sold. It reported $300,000 in profit before overhead, which is a solid 25% product profit margin. This proves the company can make and sell its devices profitably.
• Paying Off Debt: Picard wiped out over $10 million in debt using cash and by trading debt for stock. In May 2026, Picard raised $5 million in cash by selling new shares. While issuing new shares does dilute existing investors a bit (meaning your ownership percentage shrinks slightly), it was a necessary move that helped bring Picard's main debt down to a highly manageable $1.3 million.

3. Why does this matter for investors?

• A Stronger Survival Plan: Picard must submit a rescue plan to the exchange by June 7, 2026, showing how it will boost its net worth. The new $5 million in cash and the $10 million debt reduction easily fix the negative $1.4 million net worth issue, putting Picard in a great position to get approved.
• The Big Loss is Misleading: Picard reported a total loss of $7.6 million for the quarter. However, don't let that scare you away—most of this came from one-time, non-cash accounting fees related to wiping out its debt. It does not reflect the actual health of the daily business.
• Future Tech is on Track: Picard's pipeline is safe. The company is still actively developing its next-generation "Emperor" artificial heart. This fully implantable, driverless system is scheduled to start clinical trials in 2028.

4. What happens next?

• The Plan (June 7, 2026): CEO Patrick NJ Schnegelsberg and his team will submit their compliance plan. If the exchange accepts it, Picard keeps its listing while the exchange monitors its progress.
• The Deadline (November 8, 2027): Picard has until late 2027 to officially meet the exchange's ongoing net worth rules and permanently remove the "BC" warning from its ticker.

5. The Bottom Line

Picard's life-saving technology is selling well, and management is doing the heavy lifting to clean up the company's books. Because of the listing warning, the stock price might swing wildly in the short term. However, the actual risk of the company going under looks much lower today than it did just a few weeks ago.

Your next move: Keep a close eye on the news around June 7, 2026. If the NYSE American accepts Picard's rescue plan, it could be a major green light for the stock.